Missense variant in SRCAP with distinct DNA methylation signature associated with non‐FLHS SRCAP‐related neurodevelopmental disorder
American Journal of Medical Genetics Part A · 2023
DOI: 10.1002/ajmg.a.63329 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2023. Verfasst von Alexandre White-Brown und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Neurodevelopmental Disorders, Intellectual Disability, Abnormalities, Multiple. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: CIHR, Genome Prairie, Genome British Columbia.
Abstract (Originalsprache)
Floating‐Harbor syndrome (FLHS) is a neurodevelopmental disorder (NDD) caused by truncating variants in exons 33 and 34 of the SNF2‐related CREBBP activator protein gene ( SRCAP ). Truncating variants proximal to this location in SRCAP result in a non‐FLHS SRCAP‐associated NDD; an overlapping but distinct NDD characterized by developmental delay with or without intellectual disability (ID), hypotonia, normal stature, and behavioral and psychiatric issues. Here, we report a young woman who initially presented in childhood with significant delays in speech and mild ID. In young adulthood, she developed schizophrenia. On physical examination, she had facial features suggestive of 22q11 deletion syndrome. After non‐diagnostic chromosomal microarray and trio exome sequencing (ES), a re‐analysis of trio ES data identified a de novo missense variant in SRCAP that was proximal to the FLHS critical region. Subsequent DNA methylation studies showed the unique methylation signature associated with pathogenic sequence variants in non‐FLHS SRCAP‐related NDD. This clinical report describes an individual with non‐FLHS SRCAP‐related NDD caused by an SRCAP missense variant, and it also demonstrates the clinical utility of ES re‐analysis and DNA methylation analysis for undiagnosed patients, in particular, those with variants of uncertain significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
- Genetics and Genome Biology Program, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
ORCID-Profile: Rosanna Weksberg, David Dyment
Förderung
- CIHR
- Genome Prairie
- Genome British Columbia
- Genome Alberta
- Canadian Institutes of Health Research
- Ontario Genomics Institute
- Genome Canada
- Children's Hospital of Eastern Ontario Foundation
Zitieren
APA
White-Brown, A., Choufani, S., Care4Rare Canada Consortium, Weksberg, R., & Dyment, D. (2023). Missense variant in SRCAP with distinct DNA methylation signature associated with non‐FLHS SRCAP‐related neurodevelopmental disorder. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63329
Vancouver
White-Brown A, Choufani S, Care4Rare Canada Consortium, Weksberg R, Dyment D. Missense variant in SRCAP with distinct DNA methylation signature associated with non‐FLHS SRCAP‐related neurodevelopmental disorder. American Journal of Medical Genetics Part A. 2023. doi:10.1002/ajmg.a.63329
BibTeX
@article{WhiteBrown2023,
author = {White-Brown, Alexandre and Choufani, Sanaa and Care4Rare Canada Consortium, Care4Rare Canada Consortium and Weksberg, Rosanna and Dyment, David},
title = {Missense variant in SRCAP with distinct DNA methylation signature associated with non‐FLHS SRCAP‐related neurodevelopmental disorder},
journal = {American Journal of Medical Genetics Part A},
year = {2023},
doi = {10.1002/ajmg.a.63329}
}
EUVIMED